Tereza Rojko

Dr. Tereza Rojko


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
TRTereza Rojko
Tereza Rojko
PBPetra Bogovič
Petra Bogovič
SLStanka Lotrič-Furlan
Stanka Lotrič-Furlan
KOKatarina Ogrinc
Katarina Ogrinc
TCTjaša Cerar-Kišek
Tjaša Cerar-Kišek
FSFranc Strle
Franc Strle

2 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
DKDarja Kese
Darja Kese
AOAljoša Obreza
Aljoša Obreza
TRTereza Rojko
Tereza Rojko
TKTjaša Cerar Kišek
Tjaša Cerar Kišek
Legionella pneumophila is the causative agent of severe Legionnaires’ disease (LD). Although an increasing number of LD cases have been observed, published data from Slovenia are very limited and data on molecular epidemiology are even scarcer. The present retrospective study (2006–2020) reports the results of the microbiological diagnosis of LD, as well as the epidemiology and characterization of the Legionella clinical isolates. We tested urine samples from 15,540 patients with pneumonia symptoms for L. pneumophila infection by urine antigen test, of which 717 (4.6%) tested positive. Isolation of L. pneumophila was successfully performed from 88 clinical specimens, with 82 (93.2%) being identified as L. pneumophila sg 1 and six (6.8%) as L. pneumophila sg 2–14. Sequence-based typing (SBT) identified 33 different sequence types (STs), the most frequent being ST1 and ST23. Sequence type 1 mainly comprised isolates belonging to the Philadelphia subgroup, and ST23 mostly to Allentown/France. The standard SBT scheme, as well as Dresden phenotyping for L. pneumophila, presented a high diversity among isolates.

1 February 2017 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
KOKatarina Ogrinc
Katarina Ogrinc
GWGary P Wormser
Gary P Wormser
PVPaul Visintainer
Paul Visintainer
VMVera Maraspin
Vera Maraspin
SLStanka Lotrič-Furlan
Stanka Lotrič-Furlan
FSFranc Strle
Franc Strle

2 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVera Maraspin
Vera Maraspin
PBPetra Bogovič
Petra Bogovič
TRTereza Rojko
Tereza Rojko
KOKatarina Ogrinc
Katarina Ogrinc
Eva Ružić-SabljićEva Ružić-Sabljić
Eva Ružić-Sabljić
FSFranc Strle
Franc Strle
The study evaluated the course and outcome of erythema migrans in patients receiving tumour necrosis factor-alpha (TNF-α) inhibitors. Among 4157 adults diagnosed with erythema migrans in the period 2009–2018, 16 (2.6%) patients were receiving TNF-α inhibitors (adalimumab, infliximab, etarnecept, golimumab), often in combination with other immunosuppressants, for rheumatic (13 patients) or inflammatory bowel (three patients) disease. Findings in this group were compared with those in 32 sex- and age-matched immunocompetent patients diagnosed with erythema migrans in the same years. In comparison with the control group, the immunocompromised patients had a shorter incubation period (7 vs. 14 days; p = 0.0153), smaller diameter of erythema migrans (10.5 vs. 15.5 cm; p = 0.0014), and more frequent comorbidities other than immune-mediated diseases (62.5% vs. 25%, p = 0.0269), symptoms/signs of disseminated Lyme borreliosis (18.8% vs. 0%, p = 0.0324), and treatment failure (25% vs. 0%, p = 0.0094). After retreatment with an antibiotic, the clinical course of Lyme borreliosis resolved. Continuing TNF inhibitor treatment during concomitant borrelial infection while using identical approaches for antibiotic treatment as in immunocompetent patients resulted in more frequent failure of erythema migrans treatment in patients receiving TNF inhibitors. However, the majority of treatment failures were mild, and the course and outcome of Lyme borreliosis after retreatment with antibiotics was favourable.

Verified
Journal Article
Open access
PDF file
VMVera Maraspin
Vera Maraspin
PBPetra Bogovič
Petra Bogovič
KOKatarina Ogrinc
Katarina Ogrinc
TRTereza Rojko
Tereza Rojko
Eva Ružić-SabljićEva Ružić-Sabljić
Eva Ružić-Sabljić
FSFranc Strle
Franc Strle
To assess whether differences in presentation between US and European patients with early Lyme borreliosis are due to the lower rate of spirochetemia in Europe, we compared multiple variables for patients with erythema migrans (EM), restricting the analysis to subjects with a positive blood culture at the time of presentation: 93 US patients infected with Borrelia burgdorferi versus 183 European patients infected with Borrelia afzelii (No = 144) or Borrelia garinii (No = 39). Compared to spirochetemic Slovenian EM patients infected with B. afzelii, US patients with a positive blood culture significantly less often recalled a preceding tick bite at the site of the EM skin lesion, had a shorter duration of EM prior to diagnosis and more often had multiple EM lesions, regional lymphadenopathy, constitutional symptoms, an increased ESR value, a low blood lymphocyte count and detectable borrelia antibodies in acute and convalescent phase blood samples. Similar differences were observed when US patients were compared to Slovenian patients with B. garinii infection, but not all reached statistical significance. The findings are comparable to those previously reported for the corresponding skin culture positive patients and do not support the hypothesis that a higher frequency of spirochetemia at the time of presentation in US patients with EM, compared with European EM patients, is the reason for the observed differences.

1 October 2016 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
TRTereza Rojko
Tereza Rojko
MKMisa Korva
Misa Korva
SLStanka Lotrič-Furlan
Stanka Lotrič-Furlan
FSFranc Strle
Franc Strle
TATatjana Avsic-Zupanc
Tatjana Avsic-Zupanc